Omicron BA.1-Tailored mRNA COVID-19 Vaccine Safe, Immunogenic In Young Children, Study Finds

Infectious Disease Advisor (5/15, Kuhns) reports, “When administered as a 2-dose primary series or a booster, the omicron BA.1 variant-containing COVID-19 vaccine (mRNA-1273.214) is immunogenic against BA.1 and D614G in children aged 6 months to 5 years, with a safety profile comparable to mRNA-1273, according to study results published in” The Lancet Infectious Diseases. In the study, the vaccine “induced neutralizing antibody (nAb) levels against BA.1 (geometric mean concentration [GMC], 1889.7; 95% CI, 1430-2497.2) that were superior to those induced by mRNA-1273 (GMC, 74.3; 95% CI, 67.7-81.7), with superiority demonstrated at day 57 (estimated geometric mean ratio [GMR], 25.4; 95% CI, 20.1-32.1).”